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Volume 60, Number 4 Abstracts 1101Conclusions: This study demonstrates that CAS fractures are not
associated with an increased risk of restenosis. The true incidence of stent
fracture may be underestimated by x-ray analysis due to limited resolution
and frequent artifacts. Additional methods to evaluate for subtle CAS frac-
tures may assist in deﬁning a more precise incidence and might lead to
insight into the potential etiologies. Further evaluation with a larger study
population and a longer follow-up both for stent integrity and its association
with restenosis or adverse clinical outcomes is needed.
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Objectives: Inferior vena cava (IVC) thrombosis is an uncommon
condition but can cause devastating complications to those affected. Histor-
ically, this has been treated with an open surgical approach, with high
morbidity, and with angioplasty in more recent years. We describe technical
aspects of IVC stenting in patients with recalcitrant chronic occlusive disease
and evaluate its outcomes.
Methods: We reviewed all of the patients treated in an endovascular
fashion for venous pathology at our institution from 2005 to 2014 to iden-
tify and include those with IVC stent placement. Clinical characteristics,
treatment details, and outcomes data were collected using medical records.
Primary end points were technical success, symptom resolution, freedom
from reintervention, and patency rate at follow-up.
Results: Twenty-eight patients (15 males), with mean age of 48 6 14
years, underwent IVC stent placement for 16 occlusions (four congenital)
and 12 high-grade stenoses. Hypercoagulable state was noted in 14 pa-
tients, seven of whom had malignancy. A previously placed IVC ﬁlter was
present in 13 patients. Median time from onset of symptoms to
presentation was 81 months (range, 3-480 months). Lytic therapy with alte-
plase was performed in 12 patients for a mean of 2 6 1 days. Self-expanding
stents (Wallstent) were used in the IVC in 22 patients, with adjunctive use
of balloon-expandable (Palmaz) stents in seven patients. Technical success
was 100%. At a median follow-up of 10 months (range, 0-56 months),
thrombotic complications requiring reintervention occurred in four patients
at 1, 4, 8, and 37 months. One patient died at 2 weeks secondary to under-
lying malignancy. Freedom from reintervention, patency rate, and symp-
tom-free survival rate at 2 years were 84%, 90%, and 80%.
Conclusions: Endovascular stenting for chronic occlusive disease of
the IVC is safe, effective, and durable, with minimal morbidity. The reinter-
vention rate is low, with excellent outcomes.
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Objectives: This study evaluated outcomes of treated renal artery an-
eurysms (RAAs) and the natural history of observed RAAs.
Methods: A total of 114 patients with RAA managed from 1994 to
2014 were retrospectively reviewed. Primary outcomes included morbidity
and mortality of RAAs treated operatively (OP) with open and endovascular
procedures and aneurysm growth rate and risk of rupture in patients
managed nonoperatively (NOP). Secondary outcomes included renal artery
patency and need for reintervention in the OP group and kidney function in
the OP and NOP groups.
Results: There were 49 OP patients (34 females) and 66 NOP (31
females). Three RAAs ruptured (sizes: 34, 36, and 41 mm). Mean aneurysm
size was 26.8 6 8.9 mm (OP) and 13.6 6 5.2 mm (NOP; P < .001). A
total of 57% of patients in OP were symptomatic, with ﬂank pain (24%), he-
maturia (18%), and severe hypertension (18%). Nine (19%) and 29 (60%) of
OP patients had a RAA <20 and <30 mm, respectively. RAA location in the
OP included the primary bifurcation in 28, main renal artery in 8, upper and
lower segmental pole branches in 5 each, and middle segmental pole branch
in 2. Operative management included RAA resection and saphenous vein
graft (SVG) in 15, vein patch in 11, primary repair in 7, ex vivo reconstruc-
tion in 7, Dacron graft in 2, internal iliac artery patch in 1, and endovascularcoil embolization in 3. Mean renal ischemia time was 56 6 48 minutes (ex
vivo: 151 6 27 minutes; not ex vivo: 40 6 27 minutes). The 30-day mor-
tality was 0%. One patient had a nephrectomy at the time of repair due to
venous injury, and a second one occurred at 3.7 months due to SVG occlu-
sion. One patient underwent concomitant splenectomy. One patient’s oper-
ation was aborted due inﬂammation from a previously ruptured and coiled
RAA, who subsequently underwent deﬁnitive embolization. Complications
included pancreatitis (n ¼ 1) and reexploration for small bowel obstruction
(n ¼ 1) and bleeding (n ¼ 1). RAA reintervention was 0%. NOP RAAs were
followed up for 76.8 6 54.4 months and had a growth rate of 0.3 6 0.9
mm/y. There were no ruptures and no conversions to OP. Kidney function
in NOP remained stable (D glomerular ﬁltration rate, 5.4 6 21.1 mL/min)
but worsened in OP (D glomerular ﬁltration rate, 5.9 6 23.5 mL/min;
P ¼ .008).
Conclusions: No RAA <34 mm ruptured. Because the rate of
growth is slow and kidney function remains stable without repair, RAA
<30 mm should be observed unless symptoms occur.
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H. Bjarnason: None; M. Kalra: None; G. Oderich: None; M. Fleming:
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Objectives: Carotid endarterectomy (CEA) is usually performed with
eversion (ECEA) or conventional (CCEA) techniques. Previous studies
report conﬂicting results with respect to outcomes for ECEA and CCEA.
We compared patient characteristics and outcomes for ECEA and CCEA.
Methods: Deidentiﬁed data for CEA patients were obtained from the
Society for Vascular Surgery Vascular Quality Initiative database. Patients
undergoing reoperative CEA or CEA concurrent with cardiac surgery
were excluded, leaving 2828 ECEA and 20,831 CCEA for comparison.
Univariate analysis compared patients, procedures, and outcomes. Survival
analysis was also performed for primary outcomes of mortality, cerebral
ischemic events, restenosis, and reintervention.
Results: Groups were similar with respect to gender, comorbidities,
and preoperative neurologic symptoms, except that ECEA patients tended
to be older (71.3 vs 69.9 years; P < .0001). CCEA was more often per-
formed with general anesthesia (92% vs 81%; P < .001) and with a shunt
(59% vs 24%; P < .001). Perioperative ipsilateral neurologic events (ECEA,
1.3% vs CCEA, 1.2%; P ¼ .90) and any stroke (1.0% vs 0.8%; P ¼ .38)
were uncommon in both groups. ECEA tended to take less time (100 vs
113 minutes; P < .001) but more often required a return to the operating
room for bleeding (1.4% vs 0.8%; P ¼ .003). Kaplan-Meier 30 day freedom
from stroke or death was similar (97.7% vs 97.6%; P ¼ .17). The 1-year
freedom from recurrent stenosis >50% was lower for ECEA (88.9% vs
94.1%; P < .0001). However, ECEA and CCEA both had a very high rate
of freedom from reoperation at 1 year (99.6% vs 99.5%; P ¼ .98).
Conclusions: ECEA and CCEA appear to provide similar freedom
from neurologic morbidity, death, and reintervention. ECEA was associated
with signiﬁcantly shorter procedure times. Furthermore, ECEA obviates the
expenses of a patch, typically used in CCEA, and a shunt, more often used in
CCEA in this database. However, these potential beneﬁts may be reduced
by a slightly greater requirement for early return to the operating room
for bleeding.
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None; S. E. Musicant: None; N. H. Patel: None; S. Kim: None.
Cost Analysis of Trellis Device Versus Catheter-Directed Thrombolysis
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Objectives: This study assessed total costs for lower extremity
deep vein thrombosis (DVT) treatment using the Trellis device or
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device would have lower overall hospital costs than CDT.
Methods: This was a retrospective cohort study of consecutive pa-
tients who received thrombolysis for lower extremity DVT from 2010 to
2013 at a private practice vascular surgery group. The observational design
meant no intervention randomization, only a review of performed proce-
dures. Indication included presence of symptomatic thrombosis of the
deep venous system of the lower extremity. Patients underwent pharmaco-
mechanical thrombolysis using Trellis device or only CDT at treating sur-
geon’s discretion. Patients were grouped by procedure method and patient
characteristics and surgical details taken from initial history and physical ex-
amination and operative notes. Analyses were based on comparing procedure
methods and variables associated with hospital costs (ie, Fisher exact test,
Wilcoxon rank sum, or bivariate linear regression with data transformations).
All pairwise comparisons were corrected with Bonferroni method.
Results: There were 57 procedures performed during the study period,
with 10 excluded due to the patient having Paget-Schroetter syndrome, use of
another device (Angiojet), or prior DVT treatment within the previous
month. The ﬁnal study sample consisted of 47 patients, with 79% treated
with the Trellis device (35% of these patients also received CDT). Patient pro-
cedure and outcome data were similar for use of inferior vena cava ﬁlter, com-
plications, length of stay, and direct facility costs (P> .05; Table). Treatment
groups differed on the number of endovascular suite trips (P < .05). Exami-
nation of factors associated with direct facility costs were treatment group
(with Trellis plus CDT costing statistically more than Trellis alone
[r2¼0.17; P ¼ .0292]) and length of stay (r2¼0.39; P < .0001).
Conclusions: This study presents one of the largest documented re-
views of cost data related to the Trellis device. Results revealed treatment
and length of stay as being signiﬁcantly associated with cost. Further ana-
lyses with a greater sample size, along with multivariate analyses, are needed
to best understand cost-predictors related to the treatment of lower extrem-
ity DVT in similar samples.Table. Bivariate comparisons of deep vein thrombosis (DVT) patient
characteristics based on Trellis intervention status (n ¼ 47)
Variablesa
Trellis patient
(n ¼ 37)
Non-Trellis
patient (n ¼ 14) P valueb
Male sex 15 (41) 4 (40) >.9999
Age, years 49 (32-64) 51 (45-58) .9402
Symptoms
Subacute 5 (13) 0 (0) .2446
Acute 28 (76) 7 (70)
Chronic 3 (8) 3 (30)
Unknown 1 (3) 0 (0)
IVC ﬁlter used 21 (57) 8 (80) .1798
Trips to the
endovascular suite
1 (1-2) 2.5 (2-3) <.0010
Complicationc 2 (5) 3 (30) .0573
Hospital length of stay 4 (2-5) 5 (2-8) .9379
Total cost of
hospital stay (USD)
8070
(5618-9833)d
8621
(7422-11798)
.9402
IVC, Inferior vena cava; USD, United States dollars.
aContinuous data are presented as medians (interquartile range) and cate-
goric data as number (%).
bP values are based on the Fisher exact test or the Wilcoxon rank sum test.
cDeﬁned as hematoma, pulmonary embolus, or recurrent deep vein
thrombosis #1 month following treatment.
dMedian direct facility cost of $6068 for Trellis and $9207 Trellis with
catheter-directed thrombolysis.
Fig 1. Age-matchedcontrols (Cntrl) anddeepvenous thrombosis (DVT)+mice.Author Disclosures: J. H. Rinker: None; D. Massop: None; H. L.
Smith: None; P. Wall: None.
Role of Type II Endoleak in Abdominal Aortic Aneurysm Sac
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Objectives: Endovascular repair (EVAR) of infrarenal aortic aneu-
rysms (AAAs) is increasingly used in patients with suitable aortic
morphology. Despite improvements in graft design, type II endoleak
(EL-2) from the inferior mesenteric artery (EL-IMA) or lumbar artery
(EL-LA) remains the Achilles’ heel of EVAR. This study evaluated the nat-
ural history of the AAA sac after EVAR. Our hypothesis was that persistent
EL-2 is associated with inferior AAA sac regression.Methods: A retrospective analysis of all nonruptured AAA treated by
elective EVAR using Food and Drug Administration-approved endografts
from January 2005 to December 2008 in our facility was performed. Review
of medical records and preoperative and follow-up computed tomography
angiograms (CTA) at 1, 6, and 12 months were performed. Patients with
type I, III, and IV endoleaks were excluded. Persistent EL-2 was deﬁned
as EL-2 present on CTA at 6 months post-EVAR. AAA size and volume
were analyzed using Aquarius TeraRecon software. Changes in AAA sac vol-
ume at 6 and 12 months were compared in patients (1) with and without
EL-2 and (2) with an occluded vs patent IMA.
Results: The study cohort comprised 197 patients (164 men, 33
women) who were a mean age of 74 years. Mean preoperative AAA diam-
eter was 5.5 cm, and volume was 137.45 cm3 (range 4-11 cm). EL-2 was
present in 27% at completion of EVAR and persisted in 9% at a mean
follow-up of 6 months (range, 4-8 months). EL-LA resolved in 94% on
follow-up vs 55% of EL-IMA (P ¼ .01 by Fisher exact test). Preoperatively,
the IMA was occluded by coils or chronically occluded in 92 patients vs
105 patients who had a patent IMA. At the 6-month follow-up, patients
with an occluded IMA had an EL-2 rate of 2.5% vs 13% in those with a patent
IMA (P ¼ .007 by t-test). Sac volume regression was 39.5% in those with an
occluded IMA vs 29% in those with a patent IMA (P ¼ .04 by Fisher test).
Regression in AAA sac volumewas highly signiﬁcant in patients with occluded
IMA at 60% vs 41.6% at 1 year (P ¼ .0010, two- sided t-test).
Conclusions: The presence of persistent EL-2 after EVAR results in
inferior AAA sac regression. The majority of EL-LA spontaneously throm-
bose by 6 months; however, 45% of EL-IMA are persistent. Consideration
should be given to preoperative coiling of a patent IMA before EVAR.
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